Advertisement
Advertisement
CSBR
Champions Oncology, Inc.
5.80
USDSponsored
+0.02
+0.29%
Mar 25, 16:00 UTC -4
Closed
Pre-Market
5.88
+0.08
+1.38%
CSBR Earnings Reports
Positive Surprise Ratio
CSBR beat 17 of 32 last estimates.
53%
Next Report
Date of Next Report
Jul 21, 2026
Estimate for Q4 26 (Revenue/ EPS)
$13.14M
/-$0.05
Implied change from Q3 26 (Revenue/ EPS)
-20.63%
/+150.00%
Implied change from Q4 25 (Revenue/ EPS)
+6.38%
/-28.57%
Champions Oncology, Inc. earnings per share and revenue
On Mar 12, 2026, CSBR reported earnings of -0.02 USD per share (EPS) for Q3 26, missing the estimate of 0.09 USD, resulting in a -121.79% surprise. Revenue reached 16.56 million, compared to an expected 16.95 million, with a -2.27% difference. The market reacted with a +6.27% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 3 analysts forecast an EPS of -0.05 USD, with revenue projected to reach 13.14 million USD, implying an increase of 150.00% EPS, and decrease of -20.63% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
Relmada Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.28
Surprise
-103.08%
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.01
Surprise
-361.54%
FAQ
What were Champions Oncology, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Champions Oncology, Inc. reported EPS of -$0.02, missing estimates by -121.79%, and revenue of $16.56M, -2.27% below expectations.
How did the market react to Champions Oncology, Inc.'s Q3 2026 earnings?
The stock price moved up 6.27%, changed from $5.74 before the earnings release to $6.10 the day after.
When is Champions Oncology, Inc. expected to report next?
The next earning report is scheduled for Jul 21, 2026.
What are the forecasts for Champions Oncology, Inc.'s next earnings report?
Based on 3
analysts, Champions Oncology, Inc. is expected to report EPS of -$0.05 and revenue of $13.14M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement